The UL16 gene of human cytomegalovirus (HCMV) encodes a predicted translation product with features characteristic of glycoproteins (signal and anchor sequences and eight potential N-linked glycosylation sites).
a lacZ expression cassette was constructed by insertional mutagenesis. Analysis of the phenotype of the recombinant virus indicated that the UL16 gene product is nonessential for virus infectivity and growth in tissue culture.
Analysis of the coding content of the human cytomegalovirus (HCMV) genome has revealed the existence of a large number of genes that lack homologs in members of the alpha herpesvirus and gammaherpesvirus subgroups (7) . Notable among these are a very large number of genes whose predicted translation products have the characteristics of glycoproteins. Thus, of 54 probable HCMV glycoprotein genes, only two encode predicted products with discernible homology with glycoproteins of other herpesviruses; UL55 encodes the homolog of herpes simplex virus type (HSV-1) gB (9) , and UL75 encodes the homolog of HSV-1 gH (10, 32) . These proteins are conserved in alpha-, beta-, and gammaherpesviruses (gB [5, 9, 11, 25, 33, 34] and gH [10, 14, 30] ) and in HSV have been shown to be essential for virion entry (6, 13) . The view that the HCMV homologs also function in virus entry is supported by the fact that antibodies specific for these proteins neutralize virus infectivity (9, 10, 23, 35, 37, 38) .
Many studies have used HCMV-specific monoclonal antibodies or polyclonal sera to enumerate and characterize HCMV-specific glycoproteins (9, 10, 12, 16, 18, 23, 36, 37, 38) , though a comparison of different studies is often difficult because of the use of different nomenclature. Gretch et al. (18) identified three distinct disulfide-linked glycoprotein complexes in the HCMV envelope which they designated gcI, gcII, and gcIII. gcI corresponds to the HSV-1 glycoprotein B homolog, which in HCMV is composed of disulfidelinked heterodimers generated by proteolytic cleavage of the UL55 gene product (2, 3, 16) . Gretch et al. (17) proposed that gcII includes the products of the HXLF-1 and HXLF-2 genes (designated US11 and US10 by Chee et al. [7] ), and gcII has recently been identified as a heparin-binding component of the virion envelope (22) . The HXLF gene family (or US6 family) was analyzed by Weston and Barrell (44) ment mutagenesis has shown that members of the US6 family are dispensable for HCMV growth in culture (20, 21) . The major component of gcIII is gH (or p86), the UL75 gene product (10, 32, 38) . HCMV gH is disulfide linked to the UL115 gene product (24) , and gcIII corresponds to the gH:gL complex of HSV-1 (19) . We know very little about the products of the remaining potential glycoprotein genes, and our only clue to their function comes from analysis of sequence homology with known mammalian genes. For example, the UL18 ORF encodes a class I major histocompatibility complex homolog (1, 4) , and three genes (UL33, US27, and US28) encode products homologous with G-protein receptors (7) .
In this report, we describe the characterization of the UL16 gene product. The gene is predicted to encode a class I transmembrane glycoprotein which has no homologs in current data bases. We have used two approaches to study the gene product. First, antisera raised against the gene product expressed in a prokaryotic system were used to characterize the protein synthesized in a eukaryotic system and in HCMV-infected cells. Second, the UL16 gene was inactivated by insertional mutagenesis, and the in vitro phenotype of the mutant virus was examined. We conclude that UL16 encodes a 50-kDa glycoprotein that is synthesized with early kinetics and is present in HCMV-infected cells but not in the virion envelope. The protein is dispensable and has no effect on the growth characteristics of HCMV in human fibroblasts in culture. derived from it were grown in BHK cells, and infectivity was determined by plaque assay on 143 TK-cell monolayers as previously described (28) . HCMV particles were purified from tissue culture medium by tartrate gradient centrifugation (41) . Purified virus particles were examined by electron microscopy, and particle numbers were estimated by comparison with latex beads (approximately 250 nm in diameter) of known concentration, using the loop drop method (43) .
MATERIALS AND METHODS

Cells
Construction of a recombinant vaccinia virus expressing the HCMV UL16 gene. A recombinant vaccinia virus expressing HCMV UL16 was constructed by the general strategy described by Mackett et al. (27, 28) as follows. The entire UL16 ORF frame was isolated from plasmid pAT153 containing the 8.68-kb HindIII 0 fragment of the HCMV genome (31) as an NarI fragment (nucleotides 22407 to 23331). The 924-bp NarI fragment was end repaired and cloned into the SmaI site in the polylinker of pUC19, to allow the use of other restriction sites in the polylinker for subsequent cloning steps. The UL16 ORF was excised from the pUC19-based plasmid by digestion with SalI (a restriction site in the polylinker 5' to the UL16 gene); this procedure was followed by end repair using Klenow polymerase and then digestion with EcoRI (a site in the polylinker 3' to the UL16 gene). The UL16 fragment was then cloned into SmaI-EcoRI-digested pRK19 (26) Preparation of cytoplasmic RNA. Confluent monolayers of MRC5 cells were infected with HCMV strain AD169 at an MOI of 10. For immediate-early RNA, the cells were maintained in growth medium containing 100 ,ug of cycloheximide per ml, and RNA was prepared 12 h after infection. For early RNA, the cells were maintained in growth medium containing 100 ,ug of phosphonoacetic acid per ml, and RNA was prepared 24 h after infection. For late RNA, cells were harvested at 72 h after infection with no drug treatment. To prepare RNA, cells were lysed on ice in 0.1 M NaCl-0.01 M Tris-HCl (pH 7.5)-i mM EDTA containing 0.5% Nonidet P-40. Nuclei were removed by centrifugation; the supernatant was made 1% with respect to SDS and then extracted three times with phenol-chloroform and once with chloroform.
Northern (RNA) blot analysis. RNA samples (5 ,ug) dissolved in 20 mM morpholinepropanesulfonic acid (MOPS; pH 7)-i mM EDTA-5 mM sodium acetate (MOPS buffer)-50% formamide-2 M formaldehyde were incubated at 60°C for 5 min prior to loading onto 1.5% agarose gels containing 2 M formaldehyde prepared in MOPS buffer. After electrophoresis, the separated RNA was transferred to nitrocellulose membranes, baked at 80°C for 2 h, and then prehybridized in 36% formamide-75 mM sodium citrate-0.75 M sodium chloride-0.1% BSA-0.1% Ficoll-0.1% polyvinylpyrrolidone-0.1% SDS-50 mM sodium phosphate (pH 6.5)-200 jig of calf thymus DNA per ml at 55°C for 6 h.
Prehybridized membranes were then incubated with [32P]dCTP-labeled probes prepared by using a Random Prime Kit (Boehringer Mannheim) in hybridization solution (36% formamide, 75 mM sodium citrate, 0.75 M sodium chloride, 0.02% BSA, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.1% SDS, 100 ,ug of calf thymus DNA per ml, 10% dextran sulfate) at 55°C overnight. Membranes were washed three times with 0.03 M sodium citrate-0.3 M sodium chloride-0.1% SDS at 65°C (5 min each time) and three times in 1.5 mM sodium citrate-15 mM sodium chloride-0.1% SDS at 65°C for (15 min each time) and then exposed to X-ray film at -70°C with an intensifying screen.
Transfection. Transfection of MRC5 cells was performed on subconfluent monolayers by the modified calcium phosphate procedure of Chen and Okayama (8) . To construct a recombinant HCMV carrying the 3-galactosidase gene, monolayers were transfected with 20 ,g of HCMV (AD169)-infected cell DNA plus 2 ,ug of linearized plasmid DNA containing the lacZ gene inserted into the desired site in the HCMV genome. After 10 to 12 days, the progeny were harvested and sonicated. The progeny yield was determined by an immunoperoxidase assay as follows. Dilutions of transfection progeny were plated on cell monolayers, and the cells were fixed after 6 days with 85% acetone at -20°C for 10 min. The fixed monolayers were incubated with a monoclonal antibody to the HCMV 72,000-molecular-weight immediate-early antigen for 1 h at room temperature, washed thoroughly with PBS, and then incubated with biotinylated protein A followed by streptavidin-conjugated horseradish peroxidase. HCMV plaques were then detected by incubation with PBS containing 600 ,g of diaminobenzidine per ml and 0.003% hydrogen peroxide for 10 min at room temperature. 3-Galactosidase-positive plaques were visualized by counterstaining with PBS containing 2 mM MgCl2, 0.01% sodium deoxycholate, 0.02% Nonidet P-40, 5 mM potassium ferricyanide-ferrocyanide, and 5-bromo-4-chloro-3-indolyl-3-D-galactopyranoside (X-Gal) (1 mg/ml). The proportion of lacZ-positive virus to wild-type HCMV was then calculated. Appropriate dilutions of transfection progeny were then replated, and after 10 days, recombinant plaques were detected by using an overlay of 1% lowmelting-temperature agarose containing X-Gal (300 p.g/ml).
Blue plaques were picked and subjected to two rounds of plaque purification.
One-step growth cycle analysis. Confluent monolayers of MRC5 cells in 50-mm-diameter plates were infected at an MOI of 5 with either wild-type or recombinant HCMV. After adsorption for 1 h at 37°C, the inoculum was removed, the monolayers were washed twice with growth medium, and fresh medium was added to each dish. The plates were incubated at 37°C, and the growth medium was harvested at various times after infection and stored at -70°C. The titer at each time point was determined by plaque assay on MRC5 cells followed by immunoperoxidase assay or X-Gal assay for wild-type or recombinant virus as previously described.
Assay of infectious centers. Monolayers of MRC5 cells in 50-mm-diameter dishes were infected with AD169 or recombinant HCMV (100 PFU per dish). At various times after infection, the monolayers were washed with PBS and the cells were trypsinized and resuspended in 5 ml of growth medium. The number of infectious centers was determined by plating out dilutions of the infected cell suspensions and assaying for wild-type or recombinant HCMV (by immunoperoxidase or X-Gal assay as described above) 6 days later. ylated, consistent with the presence of eight potential N-linked glycosylation sites.
Initial attempts to detect the UL16 gene product in HCMV-infected cells by using serum V88 resulted in the appearance of multiple species in Western blots. Many of these species were detected nonspecifically because similar results were obtained with preimmune rabbit sera or with sera raised against other ,B-galactosidase fusion proteins. V88 serum was therefore affinity purified as described in Materials and Methods and used in Western blots to detect the UL16 gene product in HCMV-infected cells or in purified virions (Fig. 2) . A 50-kDa species was detected in UL16Vac-infected cells and in HCMV-infected cells. The UL16 product was present at early times after infection and accumulated to maximum levels at late times after infection. However, we were unable to detect the UL16 product in a -.
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RESULTS
Identification and characterization of the UL16 gene product. To identify and characterize the product of the UL16 gene, we expressed the gene in mammalian cells by using a recombinant vaccinia virus and in E. coli as a lacZ fusion protein. Sera from rabbits immunized with the purified fusion protein (V88) were used in Western blot analysis of cells infected with the UL16-expressing vaccinia virus recombinant, UL16Vac (Fig. 1) (15), was cloned into the BglII site in the polylinker in the UL16 gene. The resulting plasmid, pEgalUL16, contained the UL16 gene disrupted by the insertion of the 3-galactosidase gene driven by the HCMV major early promoter, flanked by HCMV sequences (approximately 1.5 kb upstream and 1 kb downstream of the lacZ insertion site). pEgalUL16 does not contain a poly(A) site for the lacZ gene; however, we assumed that the UL16 poly(A) site would be utilized. Since the HCMV major early promoter contains translation termination stop codons in all three frames, any UL16 N-terminal product that was expressed would lack the predicted transmembrane anchor domain.
MRC5 cells were cotransfected with HCMV AD169 DNA and linearized pEgalUL16 DNA. After 10 days, when several plaques were visible, the monolayers were harvested, sonicated, and replated on monolayers of MRC5 cells. Recombinant HCMV expressing 3-galactosidase was selected and cloned from the transfection progeny and described in Materials and Methods. Southern hybridization of the cloned virus (HCMVA&UL16) (Fig. 4) confirmed that the lacZ cassette had inserted at the correct site in the genome and that the virus was clonally pure and stable. To confirm that the recombinant virus HCMVAUL16 did not express the UL16 gene product, Western blot analysis was carried out on cells infected with wild-type HCMV or with HCMVAUL16, using affinity-purified V88 (Fig. 5) . The 50-kDa UL16 gene product was detected in the control UL16Vac-infected cells and in wild type-infected cells; however, the 50-kDa species was not detected in HCMVAUL16-infected cells, confirming that the UL16 gene was not expressed in the recombinant virus. The apparent difference in level of expression of UL16 product in wildtype-infected cells between Fig. 2 and 5 is merely a result of different exposure lengths of the autoradiographs. The higher-molecular-mass species (> 100 kDa) in the HCMVAUL16-infected cells is 3-galactosidase detected by V88, which was raised against the lacZ-UL16 fusion. We have performed several experiments to confirm that the higher-molecularmass band is in fact 3-galactosidase. The same band is also detected with other ,B-galactosidase-specific antisera and is detected in another HCMV deletion mutant which contains the lacZ gene inserted at a different locus (data not shown). Although the polyclonal antisera had been affinity purified, it is apparent that some 13-galactosidase-specific antibodies were still present.
Phenotypic characterization of HCMVAUL16 on tissue culture. To assess the effects of the insertion of the ,-galactosidase gene into the UL16 coding sequence, the ability of the recombinant virus to grow in single-cycle growth analysis (Fig. 6) and the rate of cell-to-cell spread (Fig. 7) by UL16 is not involved in determining virus infectivity, cell-to-cell spread, or release of infectious virus in tissue culture. In low-multiplicity infections, recombinant virus plaques were similar in size and morphology to wild-type plaques (not shown). Particle counts were performed on stocks of AD169 and AUL16. Particle/infectivity ratios of 180:1 and 220:1 were calculated for AD169 and AUL16, respectively, and these values were not considered to be significantly different, given the errors in particle counting and plaque assays.
DISCUSSION
Chee et al. (7) suggested that the HCMV UL16 gene encoded a glycoprotein on the basis of a predicted N-terminal signal sequence, a potential transmembrane anchor close to the C terminus, and the presence of eight potential N-linked glycosylation sites. We report in this paper that the gene product is a heavily glycosylated species of 50 kDa that is synthesized in the early phase of the growth cycle and accumulates at late times. The protein is abundant in infected cells but not detectable in purified enveloped virions. The UL16 gene is dispensable for growth in human fibroblasts in vitro, and HCMVAUL16 is indistinguishable from the parental virus AD169 in its ability to grow in human fibroblasts or to spread from cell to cell. To date, therefore, the HCMV genes UL16 (this report), UL18 (3b) and UL33 (3a), UL20 (23a), IRS1, US1 to US5, and the US6 family (20, 21) , many of which encode glycoproteins (7), have been shown to be dispensable for growth in culture. By analogy with HSV, the gB and gH:gL homologs of HCMV (the products of the UL55, UL75, and UL115 genes) can be expected to be essential for virion infectivity, but the majority of the remaining glycoproteins will probably be found to be dispensable. It is possible that some of these molecules are required for successful infection of different cell types, and it will be interesting to assess the growth of HCMVAUL16 in a variety of cells. However, it is equally likely that these HCMV glycoproteins are involved in subtle interactions of the virus with its host in vivo, and in the absence of a convenient animal model, elucidation of the function of these molecules will be a formidable problem.
